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Background: Smoking rates, and associated negative health outcomes, are disproportionately high among people
with mental illness compared to the general population. Smoke-free policies within mental health hospitals can
positively impact on patients’ motivation and self-efficacy to address their smoking. However, without post-discharge
support, preadmission smoking behaviours typically resume. This protocol describes a randomised controlled trial that
aims to assess the efficacy of linking mental health inpatients to community-based smoking cessation supports upon
discharge as a means of reducing smoking prevalence.
Methods/Design: Eight hundred participants with acute mental illness will be recruited into the randomised
controlled trial whilst inpatients at one of four psychiatric inpatient facilities in the state of New South Wales, Australia.
After completing a baseline interview, participants will be randomly allocated to receive either: ‘Supported Care’,
a multimodal smoking cessation intervention; or ‘Normal Care’, consisting of existing hospital care only. The
‘Supported Care’ intervention will consist of a brief motivational interview and a package of self-help material for
abstaining from smoking whilst in hospital, and, following discharge, 16 weeks of motivational telephone-based
counselling, 12 weeks of free nicotine replacement therapy, and a referral to the Quitline. Data will be collected
at 1, 6 and 12 months post-discharge via computer-assisted telephone interview. The primary outcomes are
abstinence from smoking (7-day point prevalence and prolonged cessation), and secondary outcomes comprise
daily cigarette consumption, nicotine dependence, quit attempts, and readiness to change smoking behaviour.
Discussion: If shown to be effective, the study will provide evidence in support of systemic changes in the provision
of smoking cessation care to patients following discharge from psychiatric inpatient facilities.
Trial registration: Australian New Zealand Clinical Trials Registry ANZTCN: ACTRN12612001042831. Date registered:
28 September 2012.
Keywords: Smoking cessation, Mental illness, Inpatient, Community, Multimodal interventionBackground
Tobacco use is the second leading cause of modifiable
morbidity and mortality worldwide [1]. In Australia, the
prevalence of smoking in the general population has
halved over the past three decades to approximately 15%
[2]. However, depending on diagnosis and setting, be-
tween 33% and 90% of people with mental illness con-
tinue to smoke [3,4]. Patients with psychotic disorders* Correspondence: alexandra.metse@uon.edu.au
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unless otherwise stated.have among the highest smoking prevalence (74% to
88%) [5]. Smokers with a mental illness also smoke more
heavily, are more nicotine dependent and find it more
difficult to quit compared to the general population
[5-7]. As a consequence, smokers with a mental illness
are more likely to have a chronic disease and to have a
shorter life expectancy [8-11].
For smokers in the general population [12,13] and for
those with a mental illness [14,15] multimodal smoking
cessation interventions, utilising both pharmacological in-
terventions (such as nicotine replacement therapy (NRT))td. This is an Open Access article distributed under the terms of the Creative
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and self-help materials), have demonstrated efficacy in in-
creasing the likelihood of quitting successfully. Interven-
tions of a longer duration and greater intensity are more
efficacious for both groups of smokers [11,16-18]. Further,
neither making a quit attempt nor successfully ceasing
smoking has been found to negatively impact on [14], and
may even improve [19-22], psychiatric health.
Hospitals have been recognised as a key setting for initi-
ating the delivery of smoking cessation care [17,20,23,24].
The implementation of total smoking bans in mental
health hospitals [11,25] and the ensuing need to manage
inpatient nicotine withdrawal [12,26] reinforces the need
to provide smoking cessation treatment in this setting
[27]. Evidence suggests that the initiation of smoking ces-
sation treatment in the inpatient psychiatric setting also
increases patient motivation and self-efficacy to change
their smoking behaviour, both as an inpatient and follow-
ing discharge [28]. However, as is the case in general
medical settings [29], evidence from psychiatric settings
suggests that without post-discharge support smoking is
likely to return to preadmission levels within 2 weeks
[30]. Such findings suggest a need for adequate and con-
sistent support to encourage a sustained quit attempt
and prevent relapse [30-32]. Systematic review evidence
from general medical settings suggests that multimodal
post-discharge cessation support of at least 4 weeks in
length or greater can result in higher rates of successful
smoking cessation [17].
A recent randomised controlled trial has demonstrated
the effectiveness of linking mental health inpatients to
community-based smoking support following discharge.
Prochaska and colleagues [20] reported a significant dif-
ference in point prevalence abstinence at 18 months
post-discharge; 20% and 7.7% for intervention and con-
trol conditions, respectively. Over a period of up to 6
months post-discharge, intervention group participants
were able to take up both pharmacological (NRT for a
total duration of up to 10 weeks) and psychosocial (face-
to-face, computer-based, and self-directed reading) smok-
ing cessation support, tailored to their readiness to stop
smoking. An opportunity may exist to enhance and ex-
tend such positive findings by providing multi-modal
smoking cessation support to all smokers, proactively and
intensively, immediately following discharge, regardless of
assessed readiness to change.
To assess the feasibility of such an approach we con-
ducted a pilot randomised controlled trial of an inter-
vention consisting of the provision of psychological and
pharmacological support to smokers admitted to one
inpatient psychiatric facility. Inpatient smokers were
randomly allocated to a multimodal smoking cessation
intervention or treatment-as-usual control. Smoking ces-
sation treatment was initiated for all smokers duringadmission and continued for a 4-month period post-
discharge with assessments made at 1 week and at 2, 4
and 6 months [33]. At the end of treatment (4 months),
participants in the intervention group had significantly
higher rates of 7-day point prevalence abstinence than
controls (11.5% versus 2%), but this difference was not
sustained at 6 months follow-up [34]. Based on the find-
ings of these previous studies, the objective of this study
is to conduct a randomised controlled trial to test the ef-
fectiveness of a multi-modal smoking cessation interven-
tion, initiated within mental health inpatient facilities for
all smokers and continued post-discharge, on 12-month
post-discharge smoking cessation rates.
Methods/Design
Study design and setting
A randomised controlled trial with blinded follow-up
will be conducted (Figure 1). Participants will be re-
cruited as inpatients at one of four acute mental health
facilities within one Local Health District in New South
Wales, Australia. At the time of recruitment, partici-
pants will be randomly allocated to either an interven-
tion (Supported Care) or control (Normal Care) group.
Participants allocated to the Supported Care condition
will receive a brief motivational interview and a package
of self-help material for abstaining from smoking whilst
in hospital, and intensive psychosocial and pharmaco-
logical support for 16 weeks upon hospital discharge.
Participants in the Normal Care condition will receive
standard hospital and discharge smoking cessation care.
Follow-up assessments will be conducted at 1, 6 and
12 months post-discharge for both conditions. The pri-
mary outcome measures comprise 7-day point preva-
lence of smoking abstinence and prolonged smoking
abstinence. Secondary outcome measures will include
number of cigarettes smoked per day, nicotine depend-
ence, quit attempts, and readiness to change smoking
behaviour. The effect of the intervention will be assessed
by comparing primary and secondary outcome measures
between intervention and control groups at each follow-
up point.
Ethics approval for the study has been obtained from
the Hunter New England Human Research Ethics Com-
mittee, HNEHREC reference no.: 11/12/14/4.02, and the
University of Newcastle Human Research Ethics Com-
mittee, reference no.: H-2012-0061. The trial is regis-
tered on the Australian New Zealand Clinical Trials
Registry ACTRN12612001042831. Date registered: 28
September 2012.
Recruitment process and inclusion criteria
Research staff (independent of the hospitals), all of
whom will receive standardised training in mental illness
and its impacts, will approach nurse unit managers in
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Figure 1 Study design. ASAP, as soon as possible; CATI, computer-assisted telephone interview; NRT, nicotine replacement therapy.
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patients. The nurse unit managers will advise whether
individual patients are sufficiently psychiatrically stabi-
lised and capable of completing the baseline interview. If
so, patients will be approached to determine if they meet
the eligibility criteria to participate in the study. Patients
will be eligible if they: are a current smoker (smoked cig-
arettes daily, weekly or less than weekly in the month
prior to admission); 18 years of age or above; understand
the research, have capacity to ask and answer questions
in relation to the benefits and potential harms (that is,
have capacity to give informed consent); and are willing
to provide contact details (including phone number and
mailing address) to facilitate communication once dis-
charged. No exclusion criteria will be applied. Patients
who meet the eligibility criteria will be given a detailedexplanation of the project requirements and invited to
participate in the trial. Informed consent will be gained
from all participants. Patients who elect not to take part,
and who are subsequently readmitted to the facility during
the recruitment phase, will be re-approached and re-
offered the opportunity to participate. Patients will only be
recruited once, regardless of the number of readmissions
within the study recruitment phase. Eight hundred partici-
pants will be recruited over a period of 18 months.
Randomisation, allocation concealment and sequence
generation
A random allocation sequence using permuted block
randomisation (with a block size of ten) will be gener-
ated by a statistician independent of the project prior to
the commencement of recruitment. Randomisation will
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nosis type to account for differences in smoking levels
and nicotine dependence (psychosis/non-psychosis type
diagnosis) [5,35]. Participant allocation to group (1:1 ratio)
will occur immediately post-baseline data collection. Re-
search staff will provide participants with a sequentially
numbered, opaque, sealed envelope. The envelope will
contain a coloured piece of paper that indicates allocation
to either the Supported Care or Normal Care condition.
Research staff involved in recruitment and outcome data
collection will be blind to the order of patient condition
assignment.
Data collection procedures
For eligible and consenting patients, baseline data will
be collected during admission via a face-to-face baseline
interview, administered by research staff in a quiet area
of the unit. The baseline data collection interview will be
developed based on previous pilot research undertaken
by the research team [33]. After the completion of the
baseline interview, clinical and demographic information
will be collected by research staff from patient medical
records.
Follow-up data will be collected via computer-assisted
telephone interviews (CATI) from all participants at 1, 6
and 12 months post-discharge. In addition, process data




Participants allocated to the Normal Care condition will
receive standard hospital smoking care only, as routinely
delivered by hospital staff. This may include brief advice
to quit, provision of NRT whilst admitted to the inpatient
facility, up to 3 days supply of NRT upon discharge, and/or
a referral to Quitline as per mandatory local area health
guidelines [26,36]. Previous research suggests that standard
hospital care is likely to be limited [37,38].
Supported care
In addition to standard smoking care provided by the
hospital, participants allocated to the Supported Care
condition will be provided with a range of evidence-
based smoking cessation supports [12,18]. Following the
baseline interview, supported care participants will be
provided with smoking cessation written self-help mater-
ial [39], including information tailored to people with
mental illness [40-42] and NRT usage advice, and a brief
motivational interview (10 to 15 minutes) designed to
evoke ambivalence regarding smoking behaviour and
reinforce positive intentions to address smoking [43].
Content of the motivational interview will encourage
consideration of: lifestyle behaviours; pros and cons ofboth continuing to smoke and quitting; impact of smok-
ing on life in 5 years from the time of interview; and im-
portance of and confidence to quit [43].
Upon discharge from hospital, all Supported Care par-
ticipants will receive a standard project pack of NRT,
which contains: seven nicotine patches (21 mg); one
nicotine inhaler with six cartridges (10 mg); 30 pieces of
nicotine gum (4 mg); and 20 nicotine lozenges (4 mg).
NRT discharge packs will also contain a brief tip sheet
for NRT use and the management of NRT side effects,
as well as a project reminder card outlining each aspect
of the intervention. Within participating units, the
process for providing discharge NRT packs will be nego-
tiated in consultation with nurse unit managers and
treating staff, in accordance with usual protocols for dis-
charge, and storage of medications. The participant’s gen-
eral practitioner and, if applicable, community mental
health team will be notified of their clients’ involvement
in the project, via the standard and automated delivery of
discharge records to relevant health professionals, and
asked to support their participation in the project [17].
Once discharged from hospital, participants in the
Supported Care arm will receive up to 16 weeks of psy-
chosocial [44] and 12 weeks of pharmacological support
[12,13,45]. Psychosocial support will initially be delivered
through five weekly telephone support calls, followed by
7 weeks of weekly or fortnightly telephone support calls
(tailored based on participants preference), tapering to 4
weeks of fortnightly support calls between weeks 12 and
16 (Figure 1). The content of the calls will be delivered
utilising a framework of motivational interviewing tech-
niques [46], and incorporate behavioural strategies to as-
sist with addressing smoking. Support call staff will
prompt participants to utilise the Quitline, and offer to
send a Quitline referral on their behalf. Support calls will
be delivered by research staff that either have a relevant
allied health qualification and/or experience working
with people with mental illness. All support callers will
receive both standardised mental health training and on-
going motivational interviewing based training and
supervision from an experienced clinical consultant.
Ongoing NRT provision will be offered by research
staff to all supported care participants, with delivery by
mail. The amount and frequency of NRT provided will
vary by participant in accordance with personal prefer-
ence, degree of nicotine dependence (measured using
time to first cigarette) [47], and nicotine withdrawal
symptoms [48]. Within the initial 12 weeks of support
post-discharge, participants are able to optionally elect
any combination of the following NRT products: patches
(21, 15, 14 or 7 mg); lozenges and/or mini lozenges (2 and
4 mg); gum (a variety of flavours; 2 and 4 mg); inhalers
(10 and 15 mg refill cartridges); oral spray (one dispenser
contains 150 × 1 mg sprays); and oral strips (2.5 mg).
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ance with an evidence-based, combination NRT algo-
rithm aimed at smokers with a high level of nicotine
dependence and who have more difficulty quitting [49].
Measures
The primary and secondary outcome measures will be col-
lected via CATI at 1, 6 and 12 months post-discharge.
Primary outcome measures
The primary outcome measure will be abstinence from
smoking, both 7-day point prevalence and prolonged ab-
stinence. Participants who report being abstinent from
smoking for 7 days or greater will be required to submit a
breath sample to validate their quit attempt. CATI inter-
viewers will organise a time to carry out this procedure
and project staff, blind to allocation group, will meet par-
ticipants in a public place or their home as soon as can be
arranged to verify abstinence. Breath samples will be taken
using a Micro+ Smokerlyser (Bedfont Scientific Ltd, http://
www.bedfont.com/smokerlyzer), where the exhaled carbon
monoxide level must not exceed 6.99 ppm for the self- re-
ported abstinence to be considered valid [50,51].
Secondary outcome measures
Secondary outcome measures will include number of ciga-
rettes smoked per day, quit attempts made (number, dur-
ation, and supports used), nicotine dependence (assessed
using the Fagerstrom Test for Nicotine Dependence) [47],
and motivation and readiness to quit (Readiness and
Motivation to Quit Smoking Questionnaire) [52].
Process measures
All participants
Details regarding the delivery of any smoking-related care
and/or support, received during the initial and any subse-
quent hospital admissions, will be collected by CATI staff
at each of the three follow-up points.
Supported care participants only
As part of the motivational interview administered following
assignment to supported care, participants will be asked to
rank on a scale from 1 to 10 both importance of, and confi-
dence to, quit smoking. To assess the degree of Supported
Care intervention delivery, descriptive data will be collected
during support calls by the designated support caller, in-
cluding: the receipt and usage of discharge NRT pack; con-
tact with, and perceived effectiveness of, Quitline support
(if applicable); intensity and duration of support calls; dose,
type, amount, usage and perceived effectiveness of NRT;
side effects of NRT use; and nicotine withdrawal symp-
toms. Data assessing the degree of participant satisfaction
with the intervention will also be collected by CATI inter-
viewers after the completion of the 12-month follow-up.Patient characteristics
Demographic and clinical information including age,
gender, marital status, mental health diagnosis (primary
and secondary), and Aboriginal and/or Torres Strait
Islander status will be collected by recruitment staff from
patient medical records, after the completion of the base-
line interview. Education levels, employment status, iden-
tity as a smoker (items based on the PRIME theory of
addiction [53]), and levels of perceived support to quit
smoking from partner, family, friends, and relevant health
professionals will be collected as part of the baseline
interview. Other patient characteristics including alcohol
consumption (Alcohol Use Disorders Identification Test)
[54], psychological distress (the six-item version of the
Kessler Psychological Distress Scale) [55], and perceived
levels of stress (the four-item version of the Perceived
Stress Scale) [56] will also be assessed at baseline and
each of the follow-up points.
Intervention cost
Descriptive data on direct costs of the intervention will
be collected as part of routine project delivery and
administration throughout the project, and include all
costs associated with inpatient and post-discharge
intervention.
Sample size
Considering 80% power with a 5% significance level, 332
participants per group will be required to detect a 4%
difference (1% versus 5% for Normal and Supported
Care participants, respectively) in prolonged abstinence
at 12 months post-discharge. This sample size will also
be adequate to detect a 10% difference in point preva-
lence abstinence at 12 months post-discharge [20].
Statistical analysis
Data will be analysed using IBM SPSS Statistics 22
(International Business Machines Corporation, http://
www-01.ibm.com/software/au/analytics/spss/).
Prior to any statistical analysis, baseline predictors of
attrition will be examined. If it appears missing data
are related to a measured aspect of the participants,
those measures will be included as covariates in the
hypothesis-testing models. The modelling strategy will
allow the use of all collected data in our estimation. Sen-
sitivity analyses will check that methods of dealing with
missing data do not have a major impact on study con-
clusions. Outcome analyses, based on coding missing
subjects as “smoking”, will allow direct comparison of
findings with the research literature.
Analysis of primary outcome measures
A linear model with estimation via Generalized Estimat-
ing Equations, using the logit link function given the
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abstinence versus smoking status at 12 months by condi-
tion. The data collected at 1 and 6 months will also
be examined; however, the 12-month follow-up will be
the primary focus. Generalized Estimating Equations, a
multivariate extension of generalised linear models, ac-
counts for dependence of responses within individuals
due to repeated measures. Any covariates identified in
preliminary data analyses may be added to the model.
Subgroup analyses will be considered, likely by depend-
ence and diagnosis (psychosis versus non-psychosis)
[5,57]. All analyses will be conducted using intent-to-
treat principles, with participants retained in their ori-
ginally assigned groups [58].
Analysis of secondary outcome measures
Chi square and t-test (or Mann–Whitney) analysis will
be used to compare the number of quit attempts, nicotine
dependence, cigarettes smoked per day, and motivation to
change smoking behaviour between the intervention and
control conditions. Descriptive statistics will be used to re-
port process data.
Discussion
Further research is needed to assess the effectiveness of
a proactive and integrated approach to the provision of
smoking cessation treatment to psychiatric inpatients
immediately upon discharge, regardless of a patient’s
assessed readiness to quit, in increasing abstinence and
secondary smoking-related outcomes. This randomised
controlled trial builds upon pilot work [33], and incor-
porates enhanced elements including a larger sample
size and greater statistical power, longer assessment of
outcomes to 12 months post-discharge, use of a more
structured motivational interviewing framework in the
delivery of psychosocial support, and a more compre-
hensive and flexible NRT protocol in the delivery of
pharmacological support.
The conduct of this trial and its findings will substan-
tively strengthen the base of evidence available to inform
the development and delivery of smoking cessation
treatment to persons with a mental illness. It will hence
contribute to redressing the significant health and social
inequities experienced by this population sub-group as a
consequence of tobacco smoking.
Trial status
Recruitment for this project commenced in October
2012, with a plan to proceed until April 2014. Follow-up
data collection has commenced; it is anticipated that it
will conclude in June 2015.
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